Albany Molecular Research, Inc.
AMRI
NASDAQ21.74
USD
- -
- -
CIK
0001065087
CUSIP
012423109
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
- -
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- IPO Date
- Feb 4, 1999
- CIK
- 0001065087
- Similar Companies
- Business
- Albany Molecular Research, Inc. (AMRI) provides integrated contract research, development, and manufacturing services to the pharmaceutical and biotechnology industries. The company offers a broad portfolio of services, including medicinal chemistry, synthetic chemistry, process research and development, analytical method development, drug substance manufacturing, and formulation development; it also provides biologics manufacturing, particle engineering, and solid-state chemistry services under brands such as AMRI's Discovery and Development Services and its GMP manufacturing capabilities. AMRI operates globally with facilities in the United States, Europe, and India, targeting pharmaceutical companies, biotech firms, and academic institutions as primary customers. Founded in 1991 and headquartered in Albany, New York, AMRI has expanded through strategic acquisitions and partnerships to enhance its end-to-end drug development platform. In recent years, the company underwent a significant transformation, including its acquisition by Carlyle Group in 2017 for approximately $1.1 billion, which transitioned it to a private entity focused on accelerating growth in contract development and manufacturing organization (CDMO) services; subsequent developments include expansions in biologics capabilities and new facility investments in 2023-2024 to support large-molecule manufacturing. No major name changes or rebrands have been reported for AMRI in the last 1-2 years, maintaining its established identity in the life sciences sector.